Spatiotemporal regulation of T cell fate decisions in cancer
癌症中 T 细胞命运决定的时空调控
基本信息
- 批准号:9350820
- 负责人:
- 金额:$ 257.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntigensAutomobile DrivingCD8-Positive T-LymphocytesCancer Cell GrowthCancer ControlCellsChromatinDevelopmentExcisionGoalsImmune systemImmunosuppressive AgentsMalignant NeoplasmsMapsMutateNormal tissue morphologyPathologicPatientsPremalignantProteinsShapesSignal TransductionSolid NeoplasmStem cellsT cell differentiationT cell regulationT-LymphocyteTechnologyTestingTissuesTumor Antigenscancer cellcancer geneticscancer immunotherapyclinically relevantdesignepigenomeexhaustfightingimmunopathologyinsightmouse modelnovelpathogenspatiotemporaltumortumorigenesis
项目摘要
PROJECT SUMMARY
The immune system has enormous power to detect and eliminate pathogens; however, harnessing this power
to fight cancer has proven challenging. A major barrier is that CD8 T cells specific for tumor-specific (mutated)
proteins and found in tumors are non-responsive and fail to eliminate cancer cells. This non-responsive state
has been thought to arise late during tumor development because tumor-specific T cells become “exhausted”
and derailed from their normal effector programming by persistent antigen exposure and/or
immunosuppressive microenvironmental factors. Using clinically-relevant genetic cancer mouse models, I
recently demonstrated that tumor-specific T cells differentiate to a non-responsive state at the pre-malignant
stage, long before the emergence of a pathologically-defined tumor. Thus, T cell non-responsiveness is not
necessarily established late during tumorigenesis, but instead already after the initial encounters with tumor
antigen. Therefore, to reprogram tumor-specific T cells for cancer immunotherapy, we must look beyond the
current framework of tumor-specific T cells as “exhausted” effectors that need to be re-invigorated and instead
design strategies to re-differentiate tumor-specific T cells out of the non-responsive fate to a functional state. In
this proposal, I plan to address three critical questions: (1) When and where are tumor-specific T cells fate
decisions made? Do signals received during the initial encounter with tumor antigen determine cell fates? (2)
How do tumor-specific T cell states in different compartments evolve after tumor resection? Is tumor-specific T
cells fate fixed, or can it evolve or change with tumor removal? (3) How can we effectively reprogram tumor-
specific T cells for the treatment of solid tumors? To achieve this goal, I propose to (i) map the temporal and
spatial factors shaping tumor-specific T cells fate decisions during tumorigenesis (ii) determine the plasticity
and chromatin states of tumor-specific T cells in different tissue compartments before and after tumor resection
and (iii) use insights gained from stem cell reprogramming studies together with novel epigenome editing
technology to re-differentiate tumor-specific T cells that will allow them to effectively control cancer cell growth
without inducing excessive immunopathology.
项目摘要
免疫系统具有巨大的检测和消除病原体的能力。但是,利用这种力量
与癌症作斗争已被证明是挑战。一个主要的障碍是CD8 T细胞针对肿瘤特异性(突变)
蛋白质并在肿瘤中发现的蛋白质无反应性,无法消除癌细胞。这种无反应状态
人们认为肿瘤特异性T细胞“耗尽”,因此被认为是在肿瘤发育后期出现的
并通过持续的抗原暴露和/或从其正常效应子编程中脱轨
免疫抑制微环境因素。使用与临床上相关的遗传癌小鼠模型,I
最近证明,肿瘤特异性T细胞在预防剂处分化为无反应状态
阶段,早在病理定义的肿瘤出现之前。那是T细胞无反应性不是
在肿瘤发生期间必须建立后期,但在与肿瘤的初始相遇之后已经建立
抗原。因此,要重新编程肿瘤特异性T细胞进行癌症免疫疗法,我们必须超越
当前的肿瘤特异性T细胞框架是“耗尽”的效果,需要重新感染,而是
将肿瘤特异性T细胞从非反应性命运中重新分化为功能状态的设计策略。
该提议,我计划解决三个关键问题:(1)肿瘤特异性T细胞何时何地
决定?在与肿瘤抗原初次相遇期间收到的信号是否确定细胞命运? (2)
肿瘤切除后不同隔室中的肿瘤特异性T细胞状态如何?是肿瘤特异性t
细胞命运固定,还是可以通过切除肿瘤而发展或变化? (3)我们如何有效地重新编程肿瘤
特定的T细胞用于治疗实体瘤?为了实现这一目标,我建议(i)绘制临时性和
肿瘤发生过程中塑造肿瘤特异性T细胞脂肪决策的空间因素(II)决定了可塑性
肿瘤切除前后不同组织室中肿瘤特异性T细胞的染色质状态
(iii)使用从干细胞重编程研究中获得的见解以及新型表观基因组编辑
重新分化肿瘤特异性T细胞的技术,该细胞将使它们有效控制癌细胞生长
没有诱导过多的免疫病理学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrea Schietinger其他文献
Andrea Schietinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrea Schietinger', 18)}}的其他基金
TOX-driven CD8 T cell differentiation and dysfunction in tumors
TOX驱动的肿瘤中CD8 T细胞分化和功能障碍
- 批准号:
10586679 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Autoimmune Stem-like CD8 T cells in Type 1 Diabetes
1 型糖尿病中的自身免疫干细胞样 CD8 T 细胞
- 批准号:
10736295 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis
早期肿瘤发生中肿瘤特异性 T 细胞状态动态和异质性
- 批准号:
9980808 - 财政年份:2016
- 资助金额:
$ 257.85万 - 项目类别:
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens
T 细胞对肿瘤抗原耐受的分子和表观遗传程序
- 批准号:
9205491 - 财政年份:2015
- 资助金额:
$ 257.85万 - 项目类别:
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens
T 细胞对肿瘤抗原耐受的分子和表观遗传程序
- 批准号:
8975841 - 财政年份:2015
- 资助金额:
$ 257.85万 - 项目类别:
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens
T 细胞对肿瘤抗原耐受的分子和表观遗传程序
- 批准号:
8424846 - 财政年份:2013
- 资助金额:
$ 257.85万 - 项目类别:
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens
T 细胞对肿瘤抗原耐受的分子和表观遗传程序
- 批准号:
8601299 - 财政年份:2013
- 资助金额:
$ 257.85万 - 项目类别:
相似国自然基金
非洲猪瘟病毒B475L蛋白靶向LMP2抑制抗原递呈的分子机制
- 批准号:32302894
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于HBV和肝癌相关抗原免疫优势T细胞表位的双靶人工抗原提呈细胞治疗HBV相关肝癌的研究
- 批准号:82303729
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KIF17介导肿瘤细胞MHC-II胞膜定位促进乳腺癌抗原提呈及免疫应答的机制研究
- 批准号:82372781
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
微量肝癌组织肿瘤新抗原高效稳定深度覆盖鉴定技术研究
- 批准号:32371503
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
钩吻素子对胃癌MHC-I类抗原呈递激活免疫应答的调控及其机制研究
- 批准号:82373138
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Molecular basis of glycan recognition by T and B cells
T 和 B 细胞识别聚糖的分子基础
- 批准号:
10549648 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Impact of tissue resident memory T cells on the neuro-immune pathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
- 批准号:
10556857 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition
绘制头颈部癌前侵袭性疾病转变的免疫基因组驱动因素
- 批准号:
10770868 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema
衰变加速因子 (CD55) 可防止香烟烟雾引起的肺气肿中凝集素途径介导的 AT2 细胞功能障碍
- 批准号:
10737359 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别:
Dissecting the role of hypoxia in T cell differentiation in cancer
剖析缺氧在癌症 T 细胞分化中的作用
- 批准号:
10578000 - 财政年份:2023
- 资助金额:
$ 257.85万 - 项目类别: